# Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/non-penicillin-beta-lactam-drugs-a-cgmp-framework-for-preventing-cross-contamination-draft-guidance-for-industry/0995d9e6-6e6d-4bdf-880c-7d5338ab692d

> FDA guidance document: Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry. Issue date: June 24, 2022. Get complete insights and analysis.

---

## Details

- Title: Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2022-06-24
- Comment Close Date: 2022-08-23
- Last Changed: 2022-06-24
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2011-D-0104">FDA-2011-D-0104</a>

## Related Documents

- [Psychedelic Drugs: Considerations for Clinical Investigations](https://www.globalkeysolutions.net/guidances/guidance-document/psychedelic-drugs-considerations-for-clinical-investigations/c22c8005-efa9-4373-893d-cf27911562b6)
- [Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/opioid-analgesic-drugs-considerations-for-benefit-risk-assessment-framework-guidance-for-industry/c20377b8-3086-48cf-be2b-b9cd12520573)
- [How To Obtain a Covered Product Authorization](https://www.globalkeysolutions.net/guidances/guidance-document/how-to-obtain-a-covered-product-authorization/881f0322-95f9-4bfd-b6c3-35f5df950808)